Alector (NASDAQ:ALEC) Insider Sells $11,246.73 in Stock

Posted by Francis Steltz on Jun 6th, 2026

Alector, Inc. (NASDAQ:ALEC – Get Free Report) insider Grace Wong-Sarad sold 5,709 shares of Alector stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $11,246.73. Following the completion of the sale, the insider directly owned 98,936 shares of the company’s stock, valued at $194,903.92. The trade was a 5.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Grace Wong-Sarad also recently made the following trade(s):

On Wednesday, June 3rd, Grace Wong-Sarad sold 3,475 shares of Alector stock. The stock was sold at an average price of $1.88, for a total value of $6,533.00.
On Thursday, April 16th, Grace Wong-Sarad sold 1,820 shares of Alector stock. The stock was sold at an average price of $2.65, for a total value of $4,823.00.
On Tuesday, March 10th, Grace Wong-Sarad sold 1,000 shares of Alector stock. The stock was sold at an average price of $2.65, for a total value of $2,650.00.

Alector Trading Down 9.7%

ALEC opened at $1.64 on Friday. Alector, Inc. has a 12 month low of $1.09 and a 12 month high of $3.40. The stock has a market capitalization of $181.53 million, a price-to-earnings ratio of -1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.25 and a quick ratio of 5.25. The business has a fifty day moving average price of $2.27 and a 200 day moving average price of $1.94.

Alector (NASDAQ:ALEC – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%.The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $9.67 million. Sell-side analysts expect that Alector, Inc. will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of Alector

Institutional investors have recently bought and sold shares of the business. Elmind Capital LP purchased a new stake in Alector during the 4th quarter worth about $1,404,000. Foresite Capital Management IV LLC purchased a new stake in Alector during the 4th quarter worth about $6,064,000. Spruce Street Capital LP purchased a new stake in Alector during the 4th quarter worth about $1,744,000. Lexington Partners L.P. lifted its holdings in shares of Alector by 429.2% in the 4th quarter. Lexington Partners L.P. now owns 53,488 shares of the company’s stock valued at $83,000 after purchasing an additional 43,380 shares during the last quarter. Finally, Hershey Trust Co. lifted its holdings in shares of Alector by 100.0% in the 4th quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock valued at $32,000 after purchasing an additional 10,286 shares during the last quarter. 85.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALEC. BTIG Research raised Alector from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Tuesday, March 10th. Cantor Fitzgerald raised Alector from a “neutral” rating to an “overweight” rating in a research note on Wednesday, April 15th. Morgan Stanley reissued an “underweight” rating and set a $2.00 target price on shares of Alector in a research note on Monday, May 4th. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alector in a research note on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.63.

Read Our Latest Stock Report on Alector

Alector Company Profile

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.